US FDA Extends Review Period for Exelixis Cancer Drug Combination

Key Facts

1The U.S. FDA has extended the review of Exelixis' experimental colorectal cancer drug combination by three months.

In a move reflecting ongoing regulatory scrutiny within the biotechnology sector, the U.S. Food and Drug Administration (FDA) has extended the review period for Exelixis' experimental colorectal cancer drug combination. According to reports, the review period has been pushed back by three months, a development disclosed by the company in a regulatory filing on Friday. This decision delays the anticipated timeline for potential approval and subsequent market entry of the treatment.

This regulatory delay comes at a critical juncture for pharmaceutical firms specializing in oncology treatments as Exelixis seeks to strengthen its innovative drug portfolio. Based on the provided facts, a three-month extension is a negative development for biotech timelines, although it does not constitute a formal rejection of the drug by health authorities.

Regarding market performance, EXEL stood at $57.43 (close September 10, 2026), having reached a day high of $58.33 and a low of $57.23 per market data. Investors will be watching for further updates from the company regarding FDA requirements in the coming months, particularly as the immediate economic calendar shows limited major catalysts directly impacting the sector.